台股 » 個股 » 生展 » 籌碼相關 » 券商分點績效 » 券商分點個股進出

生展

(8279)
  • 股價
    163.0
  • 漲跌
    --
  • 漲幅
    0.00%
  • 成交量
    0
  • 產業
    上櫃 生技醫療類股▲0.47%
  • 68人加入追蹤

    立即追蹤

  • 本地時間:09:02

     
生展 (8279)籌碼相關-凱基-東港 券商分點個股進出
券商分點績效/獲利分析

透過統計各券商分點在長期買賣某個股的操作績效,來找出真正獲利的贏家所在券商分點,進而追蹤此贏家所操作的股票與軌跡。

凱基-東港 券商分點個股進出

日期買進張數買進均價賣出張數賣出均價收盤價買賣超60日均量成交佔比 大量交易提示
2023/05/1600.000184.00180.50060-0.02%
2023/05/110178.5000.00178.500600.02%
2023/05/0800.001184.50185.00-158-1.71%
2023/05/031180.5000.00183.501581.72%
2023/04/1300.001178.00177.50-144-2.25%
2023/04/111170.0000.00171.001432.32%
2022/12/0900.000157.50160.00059-0.01%
2022/11/1700.000149.50149.500740.00%
2022/10/130143.0000.00143.0001040.00%
2022/09/260152.0000.00147.0001010.00%
2022/09/190157.0000.00157.0001020.00%
2022/08/220169.0000.00170.000810.00%
2022/05/1600.001124.50127.00-143-2.32%
2022/05/1300.000.5122.00125.00-0.543-1.15%
2022/01/2000.001117.50128.00-145-2.18%
2022/01/181114.5000.00114.501372.68%
2021/10/2700.000.589.2089.40-0.526-1.77%
2021/01/0600.001106.00106.50-130-3.26%
2020/12/3000.0014106.50107.50-1430-46.00%
2020/12/1500.001108.50108.50-132-3.10%
2020/12/1400.001111.00109.50-133-2.99%
2020/12/1000.005108.50109.50-533-14.87%
2020/12/0900.002109.00109.00-233-5.96%
2020/12/042110.7514111.11110.00-1239-30.53%
2020/10/2200.001111.00110.50-1102-0.97%
2020/09/241108.0000.00107.0011260.79%
2020/09/2200.001112.50112.50-1126-0.79%
2020/08/2000.001126.00125.50-1121-0.82%
2020/08/1900.002134.25135.00-2115-1.74%
2020/08/171130.0000.00129.5011080.92%
2020/08/071128.0000.00130.001921.08%
2020/08/0600.001127.50127.50-181-1.22%
2020/06/2400.003113.17114.00-365-4.58%
2020/05/2900.004108.00111.50-492-4.31%
2020/05/203110.0000.00111.003933.21%
2019/11/281122.0000.00119.501661.51%
2019/10/2300.001125.00124.50-182-1.22%
2019/10/210126.5000.00126.500830.02%
2019/10/151124.5000.00126.001921.08%
2019/10/041132.5000.00130.0011000.99%
2019/09/2700.004134.25133.50-4106-3.76%
2019/09/2500.001135.00135.00-1109-0.91%
2019/09/1800.001144.00143.50-1112-0.89%
2019/09/102142.2500.00142.0021131.76%
2019/09/0900.002141.50140.50-2113-1.76%
2019/07/3000.003153.00151.00-392-3.23%
2019/07/242150.0000.00150.502842.37%
2019/07/2200.002153.00154.00-281-2.45%
2019/07/112151.001149.00148.501651.53%
2019/06/1000.001121.00121.00-149-2.01%
2019/06/041120.0000.00120.001561.76%
2019/05/131119.5000.00119.501661.50%
2019/03/181122.0000.00121.001442.26%
2019/03/1510122.2000.00121.00104323.00%
2019/03/1300.004122.75122.50-441-9.70%
2019/03/1200.002121.50124.00-240-4.95%
2019/03/085117.5000.00120.0053613.61%
2019/03/072117.0000.00114.002345.77%
2019/03/061113.5000.00113.501323.06%
2019/03/051111.0000.00112.001323.11%
2019/02/221102.0000.00102.001253.93%
2019/02/215102.5000.00103.0052519.33%
2019/02/205103.5000.00103.0052519.47%
2019/02/195104.0000.00103.5052420.07%
2019/02/155104.5000.00104.5052420.28%
2018/11/2800.00194.0094.00-141-2.44%
2018/11/14193.6000.0093.501442.24%
2018/11/0800.00194.4093.00-144-2.24%
2018/10/3100.00186.5086.00-150-1.98%
2018/10/24189.00190.0089.500520.00%
2018/10/22190.00191.8091.800530.00%
2018/10/18190.5000.0090.001541.85%
2018/10/17191.4000.0091.501551.81%
2018/10/1500.00189.2091.50-155-1.81%
2018/10/12186.8000.0088.001551.81%
2018/10/05192.4000.0092.401531.87%
2018/09/1900.000.691.0091.00-0.652-1.15%
2018/08/1600.002101.00101.00-280-2.49%
2018/08/151103.0000.00102.501801.24%
2018/07/2400.001121.00122.50-1116-0.86%
2018/06/131147.0000.00147.0012820.35%
2018/06/111150.0000.00152.0012900.34%
2018/06/041157.0000.00156.5012970.34%
2018/05/161152.0000.00152.0013520.28%
2018/05/112156.0000.00155.5023580.56%
2018/05/091155.0000.00153.0013560.28%
2018/05/0300.001164.00163.00-1367-0.27%
2018/05/021158.0000.00158.5013640.27%
2018/04/1200.001160.00158.50-1335-0.30%
2018/04/092170.0000.00168.0023220.62%
2018/04/0300.001171.00167.50-1315-0.32%
2018/03/2000.001139.00140.00-1265-0.38%
2018/03/091134.5000.00136.5012920.34%
2018/03/021140.502141.25141.00-1313-0.32%
2018/02/261133.5000.00135.5013140.32%
2018/02/221135.5000.00133.0013140.32%
2018/02/211130.0000.00130.5013110.32%
〈國光生展望〉子公司安特羅腸病毒三期臨床入尾聲 明年展開IPOAnue鉅亨-2023/12/26
〈國光生展望〉流感疫苗申請巴西藥證+破傷風切新市場 外銷業績拚成長Anue鉅亨-2023/12/26
〈聯合再生展望〉洪傳獻:TOPCon技術明年成主流 獲利表現佳Anue鉅亨-2023/10/16
生展 相關文章